Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 14/20 | 0.57 |
| ▸ | JAK2 | O60674 | 3/20 | 0.57 |
| ▸ | TGFBR1 | P36897 | 6/20 | 0.51 |
| ▸ | AURKA | O14965 | 5/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.51 |
| ▸ | ABL1 | P00519 | 4/20 | 0.49 |
| ▸ | BCR | P11274 | 4/20 | 0.49 |
| ▸ | CHUK | O15111 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13986221 | 0.89 | PDPK1 (0.66) | PDPK1JAK2TGFBR1AURKAAURKB | |
| SCHEMBL13525176 | 0.85 | PDPK1 (0.65) | PDPK1JAK2TGFBR1AURKAAURKB | |
| SCHEMBL13986219 | 0.82 | JAK2 (0.56) | PDPK1JAK2TGFBR1AURKAAURKB | |
| SCHEMBL13524474 | 0.82 | PDPK1 (0.53) | PDPK1JAK2TGFBR1AURKAAURKB | |
| SCHEMBL6479941 | 0.81 | JAK2 (0.72) | PDPK1JAK2TGFBR1AURKAAURKB | |
| SCHEMBL4491663 | 0.80 | PDPK1 (0.71) | PDPK1JAK2TGFBR1AURKAAURKB | |
| SCHEMBL13524475 | 0.80 | JAK2 (0.54) | PDPK1JAK2TGFBR1AURKAAURKB | |
| SCHEMBL13986220 | 0.80 | JAK2 (0.54) | PDPK1JAK2TGFBR1AURKAAURKB | |
| SCHEMBL421269 | 0.74 | JAK2 (0.77) | PDPK1JAK2TGFBR1AURKAAURKB | |
| SCHEMBL424831 | 0.73 | PDPK1 (1.00) | PDPK1JAK2TGFBR1AURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645799-B2 | Substituted biaryl compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090062287-A1 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-05 | — | — | US | disclosed |
| US-7459564-B2 | Substituted biaryl compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062287-A1 | SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, F3, F12 | PDPK1 1904/4885JAK2 485/4885TGFBR1 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.